Low Risk MDS

Home > Low Risk MDS

12 Jul Low Risk MDS

Posted at 16:26h in by
Current Status
Not Enrolled
Price
Free
Get Started
Login to Enroll

Author: Dr. Stefan D. Jevtic

Reviewer: Dr. Dina Khalaf

Objectives

At the end of the self-assessment module, participants will be able to:

  1. Describe an approach to the initial management approach of patients with lower-risk MDS
  2. Discuss the common adverse effects of erythroid-maturation agents in patients on this therapy for MDS
  3. Explain the initiation of erythroid-maturation agents and dose adjustments for patients experiencing adverse effects.

CHS Scientific Planning Committee Members (2021-22)

Dr. Joanne Britto – Clinical Fellow, Malignant Hematology, Department of Oncology, McMaster University
Dr. Yan Xu – Fellow Physician, Hematology
Dr. Siraj Mithoowani – Clinical Hematologist at St. Joseph’s Healthcare, Hamilton
Dr. Hassan Sibai – Assistant Professor of Medicine, Faculty of Medicine, University of Toronto and Staff Physician, Division of Medical Hematology & Oncology, Princess Margaret Cancer Centre

Conflicts of Interest: None